Ag-specific mucosal IgA Ab responses following nasal immunization with MIP-1α or MIP-1β and OVA*
Vaccine . | End-point titers of anti-OVA IgA Abs . | ||
---|---|---|---|
Feces . | Vaginal wash . | Nasal wash . | |
OVA only | ≤2 | ≤2 | ≤2 |
MIP-1α plus OVA | 76.8 ± 7.5† | 22.5 ± 3.2† | 9.2 ± 1.8† |
MIP-1β plus OVA | 153.1 ± 25.3† | 60.8 ± 8.1† | 14.8 ± 1.6† |
Vaccine . | End-point titers of anti-OVA IgA Abs . | ||
---|---|---|---|
Feces . | Vaginal wash . | Nasal wash . | |
OVA only | ≤2 | ≤2 | ≤2 |
MIP-1α plus OVA | 76.8 ± 7.5† | 22.5 ± 3.2† | 9.2 ± 1.8† |
MIP-1β plus OVA | 153.1 ± 25.3† | 60.8 ± 8.1† | 14.8 ± 1.6† |
Groups of 5 C57BL/6 mice were nasally immunized on days 0, 7, and 14 with 75 μg OVA and 0.0 or 1.0 μg MIP-1α or MIP-1β. The data presented are the mean Ab titers ± SEMs of 3 separate experiments. ELISA determined the distribution of OVA-specific serum and fecal Ab titers on day 21.
Statistically significant differences (P < .05) of Ab titers of mice that received OVA alone.